Literature DB >> 7623112

Muscle atonia is triggered by cholinergic stimulation of the basal forebrain: implication for the pathophysiology of canine narcolepsy.

S Nishino1, M Tafti, M S Reid, J Shelton, J M Siegel, W C Dement, E Mignot.   

Abstract

Narcolepsy is a sleep disorder characterized by excessive daytime sleepiness and rapid eye movement (REM) sleep-related symptoms, such as cataplexy. The exact pathophysiology underlying the disease is unknown but may involve central cholinergic systems. It is known that the brainstem cholinergic system is activated during REM sleep. Furthermore, REM sleep and REM sleep atonia similar to cataplexy can be triggered in normal and narcoleptic dogs by stimulating cholinergic receptors within the pontine brainstem. The pontine cholinergic system is, therefore, likely to play a role in triggering cataplexy and other REM-related abnormalities seen in narcolepsy. The other cholinergic system that could be involved in the pathophysiology of narcolepsy is located in the basal forebrain (BF). This system sends projections to the entire cerebral cortex. Since acetylcholine release in the cortex is increased both during REM and wake, the basocortical cholinergic system is believed to be involved in cortical desynchrony. In the current study, we analyzed the effect of cholinergic compounds injected into the forebrain structures of narcoleptic and control dogs. We found that carbachol (a cholinergic agonist) injected into the BF triggers cataplexy in narcoleptic dogs while it increases wakefulness in control dogs. Much higher doses of carbachol bilaterally injected in the BF were, however, shown to trigger muscle atonia even in control dogs. These results suggest that a cholinoceptive site in the BF is critically implicated in triggering muscle atonia and cataplexy. Together with similar results previously obtained in the pontine brainstem, it appears that a widespread hypersensitivity to cholinergic stimulation may be central to the pathophysiology of canine narcolepsy.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7623112      PMCID: PMC6577869     

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  27 in total

Review 1.  Neurobiology of waking and sleeping.

Authors:  Barbara E Jones
Journal:  Handb Clin Neurol       Date:  2011

2.  Innervation of orexin/hypocretin neurons by GABAergic, glutamatergic or cholinergic basal forebrain terminals evidenced by immunostaining for presynaptic vesicular transporter and postsynaptic scaffolding proteins.

Authors:  Pablo Henny; Barbara E Jones
Journal:  J Comp Neurol       Date:  2006-12-01       Impact factor: 3.215

Review 3.  Challenges in the development of therapeutics for narcolepsy.

Authors:  Sarah Wurts Black; Akihiro Yamanaka; Thomas S Kilduff
Journal:  Prog Neurobiol       Date:  2015-12-23       Impact factor: 11.685

4.  Major histocompatibility class II molecules in the CNS: increased microglial expression at the onset of narcolepsy in canine model.

Authors:  M Tafti; S Nishino; M S Aldrich; W Liao; W C Dement; E Mignot
Journal:  J Neurosci       Date:  1996-08-01       Impact factor: 6.167

5.  Desynchronized (REM) sleep inhibition induced by carbachol microinjections into the nucleus basalis of Meynert is mediated by the glutamatergic system.

Authors:  A Manfridi; M Mancia
Journal:  Exp Brain Res       Date:  1996-04       Impact factor: 1.972

Review 6.  Clinical and neurobiological aspects of narcolepsy.

Authors:  Seiji Nishino
Journal:  Sleep Med       Date:  2007-04-30       Impact factor: 3.492

7.  A consensus definition of cataplexy in mouse models of narcolepsy.

Authors:  Thomas E Scammell; Jon T Willie; Christian Guilleminault; Jerome M Siegel
Journal:  Sleep       Date:  2009-01       Impact factor: 5.849

8.  Neuronal degeneration in canine narcolepsy.

Authors:  J M Siegel; R Nienhuis; S Gulyani; S Ouyang; M F Wu; E Mignot; R C Switzer; G McMurry; M Cornford
Journal:  J Neurosci       Date:  1999-01-01       Impact factor: 6.167

9.  The nitric oxide synthase inhibitor NG-Nitro-L-arginine increases basal forebrain acetylcholine release during sleep and wakefulness.

Authors:  Jacqueline Vazquez; Ralph Lydic; Helen A Baghdoyan
Journal:  J Neurosci       Date:  2002-07-01       Impact factor: 6.167

10.  Why we sleep: the temporal organization of recovery.

Authors:  Emmanuel Mignot
Journal:  PLoS Biol       Date:  2008-04-29       Impact factor: 8.029

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.